Kohn, Kohn and Colapinto and Athens-based Greek law firm of Pavlos K. Sarakis & Associates jointly represented Greek whistleblowers who proved that the multinational Swiss-based pharmaceutical company Novartis paid millions in bribes to illegally market drugs in violation of the Foreign Corrupt Practices Act. Novartis was required to pay over $300 million in sanctions and fines to the U.S. Securities and Exchange Commission (SEC) and the U.S. Department of Justice (DOJ).
Kohn, Kohn and Colapinto worked directly with attorneys and agents from the DOJ and SEC in this multi-year international bribery, unique because the bribes were paid to officials in a European Union country. The case included client interviews in Europe and a factual investigation in Athens, Greece. Attempts to “unmask” the identities of the whistleblowers, and retaliate against them, were intense. At one point a suspected whistleblower had a state-appointed body guards to protect his safety. The local lawyers in Greece were also assigned body guards by the Greek government to prevent retaliation.
The whistleblowers, whose identities remain strictly confidential, were fully vindicated. The whistleblowers information resulted in fines and sanctions against Novartis of over $300 million. Novartis also had to agree to extensive remedial programs to prevent bribery in the future.
This case demonstrates the broad reach of the U.S. Foreign Corrupt Practices Act (FCPA). The U.S. whistleblower laws, including the right to file cases anonymously, applied, even though the whistleblowers came from Greece, the drug company was headquartered in Switzerland, the bribes were paid in Greece, and the politicians and government employees taking the bribes were all in Greece.
The Department of Justice described the FCPA cases against Novartis as follows:
“Novartis Greece conspired with others to violate the FCPA by engaging in a scheme to bribe employees of state-owned and state-controlled hospitals and clinics in Greece in order to increase the sale of Novartis-branded pharmaceutical products. . . Novartis Greece, through its employees and agents, knowingly and willfully conspired with others to cause Novartis AG to mischaracterize and falsely record improper payments related to the international medical congresses and the epidemiological study in Novartis AG’s books, records, and accounts. . . As part of the agreement, Novartis Greece agreed to continue to cooperate with the government in any ongoing or future criminal investigations concerning Novartis Greece, its executives, employees, or agents. Novartis Greece and its parent company, Novartis AG, agreed to enhance their compliance programs and to report to the government on the implementation of their enhanced compliance programs.”
Information submitted in the client intake form or in email from anyone seeking legal help is covered under the attorney client and work product privileges to the fullest extent of the law. We also highly encourage you to learn about our intake process before submitting an intake.
Your communications are secured and sent over 256-bit SSL encryption. Protect your identity and confidentiality, do not use any devices owned or controlled by a private corporation or governmental entity. It is also recommended to protect your online identity by establishing a new email account that does not identify you and to avoid the use of other online platforms that may disclose your identity.
Subscribe to our newsletter to receive whistleblower news and resources crafted & curated by the partners and associates at KKC.
The information you obtain at this site is not, nor is it intended to be, legal advice. You should consult an attorney for advice regarding your individual situation. All information submitted in the client intake form or in email from anyone seeking legal assistance is considered covered under the attorney client and work product privileges to the fullest extent of the law. While we treat your information as confidential, a lawyer-client relationship is created only by express written agreement signed by both you and Kohn, Kohn & Colapinto.